It's Biotime's time
This morning I added Biotime (BTX) to the Barchart Van Meerten Speculative portfolio. BTX. headquartered in Emeryville, California, develops blood plasma volume expanders, blood replacement solutions for hypothermic low temperature surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment and other applications. BioTime's lead product Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp. under exclusive licensing agreements.
This is a speculative pick based on price momentum alone. The stock has a 96% Barchart technical buy signal, hit 17 new highs and is up 39.12% in the last 20 trading sessions.
The price is currently at 7.92 which is 71.65% above its 50 day moving average of 5.96. The Relative Strength index is 75.90% and risng
Jim Van Meerten is an advisor to Marketocracy Capital Managementwho uses his model portfolios not only to manage their mutual funds but also their clients Separately Managed Accounts. You can read his blogs about those model portfolios and investing here and on Barchart Portfolio Blogs. Please leave a comment below or emailJimVanMeerten@gmail.com.
Disclosure: Jim Van Meerten through Marketocracy Capital Management has an interest in the stocks mentioned in this blog.